Enveric Biosciences, Inc.
ENVBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2025 |
| Alliance Global Partners | maintain | Buy | Jun 1, 2022 |
| Aegis Capital | downgrade | Buy →Hold | Mar 8, 2022 |
| Aegis Capital | maintain | Buy | Jul 8, 2021 |
| Maxim Group | maintain | Buy | Jun 28, 2021 |
Earnings History
Next report: Nov 12, 2026| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.76 | — | — | — |
| May 15, 2026 | $-1.08 | — | — | — |
| Mar 27, 2026 | $0.85 | $-55.80 | — | — |
| Nov 14, 2025 | $-10.81 | $-63.00 | — | — |
| Aug 11, 2025 | $-11.64 | $-63.00 | — | — |
| May 13, 2025 | $-14.64 | $-72.00 | — | — |
| Mar 31, 2025 | $-57.96 | $-3.45 | — | — |
| Nov 14, 2024 | $-43.20 | $-0.52 | — | — |
News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies for its lead non-hallucinogenic, neuroplastogenic candidate EB-003. The comprehensive in vitro screen, invo.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallu.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City. In the prerecorded presentation, Dr. Tucker.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update. CEO Commentary: "The second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clin.